(NYSE:MRK), a global healthcare leader, finds itself at a crossroads as it navigates challenges in its China Gardasil business while capitalizing on opportunities in pulmonary arterial hypertension ...

We recently compiled a list of the 12 Best Blue Chip Stocks to Buy Under $100. In this article, we are going to take a look ...

Trading options involves greater risks but also offers the potential for higher profits. Savvy traders mitigate these risks ...

Merck said its board authorized an additional $10 billion share repurchase authorization, which has no time limit for completion. The maker of medicines and vaccines has a market cap of $247.75 ...

We recently published a list of Kevin O’Leary’s Stock Portfolio: 15 Stock Picks for 2025. In this article, we are going to ...

In a report released yesterday, Mohit Bansal from Wells Fargo maintained a Hold rating on Merck & Company (MRK – Research Report). The ...

Last year wasn't a good one for Merck (NYSE: MRK), one of the largest pharmaceutical companies in the world. The healthcare ...

Herrmann will continue in her role as chief of staff to EVP and chief communications and public affairs officer Cristal Downing.

Merck & Co. has won U.S. Food and Drug Administration priority review for its application seeking expanded use of its Welireg oral cancer drug in patients with rare tumors that form in and around the ...

In a report released on January 24, Daina Graybosch from Leerink Partners maintained a Buy rating on Merck & Company (MRK – Research ...

Based on a survey of cardiologist and pulmonologists treating patients for pulmonary arterial hypertension (PAH), analysts at ...

Merck & Co. and Eisai reported mixed results from a late-stage study of the cancer drugs Keytruda and Lenvima in patients with certain types of gastroesophageal cancer.